Page last updated: 2024-08-17

trifluridine and uracil

trifluridine has been researched along with uracil in 184 studies

Research

Studies (184)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (1.09)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (5.98)	29.6817
2010's	110 (59.78)	24.3611
2020's	61 (33.15)	2.80

Authors

Authors	Studies
Asao, T; Emura, T; Fukushima, M; Kazuno, H; Suzuki, N; Tada, Y; Yamada, Y; Yano, S	1
HEIDELBERGER, C; PARSONS, DG; REMY, DC	1
BOOHAR, J; HEIDELBERGER, C; KAMPSCHROER, B	1
Emura, T; Fujioka, A; Kitazato, K; Nakagawa, F; Ohshimo, H	1
Emura, T; Fukushima, M; Kitazato, K; Murakami, Y; Nakagawa, F	1
Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M	1
Harashima, H; Kamiya, H; Kuwata, K; Nagayama, S; Tsuchiya, H; Yamashita, K	1
Cleverley, J	1
Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A	1
Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E	1
de Bruin, M; Emura, T; Fukushima, M; Peters, GJ; Temmink, OH	1
Abbruzzese, JL; Fukushima, M; Hoff, PM; Kopetz, S; Kuwata, K; Mita, A; Overman, MJ; Thomas, MB; Varadhachary, G; Wolff, RA; Xiong, H	1
Abbruzzese, JL; Fukushima, M; Hoff, P; Kopetz, S; Kuwata, K; Mita, A; Overman, MJ; Varadhachary, G; Wolff, RA; Xiong, H	1
Kamoshida, S; Kuroda, M; Shintani, M; Takakuwa, Y; Urano, M	1
Boku, N; Doi, T; Fukutomi, A; Hironaka, S; Koizumi, W; Ohtsu, A; Onozawa, Y; Sasaki, T; Yoshino, T	1
Sobrero, A	1
Baba, H; Esaki, T; Hamada, C; Komatsu, Y; Mizunuma, N; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Sugimoto, N; Tanase, T; Tsuji, A; Tsuji, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T	1
Bijnsdorp, IV; Peters, GJ	1
Bijnsdorp, I; Ebbing, E; El-Naggar, M; Peters, GJ; van den Berg, J	1
Fujioka, A; Ishida, K; Kazuno, H; Matsuo, K; Nagase, H; Nakagawa, F; Oguchi, K; Okabe, H; Osada, A; Sakamoto, K; Tanaka, N; Yamada, Y; Yamamura, K; Yokogawa, T	1
Fukuoka, S; Kotani, D; Yoshino, T	1
Nakagawa, F; Nukatsuka, M; Saito, H; Sakata, M; Takechi, T; Uchida, J	1
Chung, JH; Kim, SY; Kim, TW; Kim, Y; Lee, EJ; Lee, HJ; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS	1
Ishida, K; Matsuo, K; Nakagawa, F; Okabe, H; Sakamoto, K; Takechi, T; Tanaka, N; Tsukihara, H; Uchida, J	1
Chiba, M; Nakanishi, T; Takahashi, K; Tamai, I; Yoshisue, K	1
Ishida, K; Kazuno, H; Matsuo, K; Oguchi, K; Okabe, H; Osada, A; Sakamoto, K; Tanaka, N; Ueno, H; Yamada, Y; Yokogawa, T	1
Benedetti, F; Boucher, E; Cleary, JM; Falcone, A; Garcia-Carbonero, R; Hochster, H; Ito, M; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Mizuguchi, H; Mizunuma, N; Ohtsu, A; Peeters, M; Prenen, H; Shimada, Y; Sobrero, A; Tabernero, J; Tran, B; Van Cutsem, E; Yamazaki, K; Yoshino, T; Zaniboni, A	1
Mayor, S	1
Cleghorn, S	1
Chiba, M; Komoto, I; Kuwata, K; Nakagawa, F; Oka, H; Takeuchi, M; Yamashita, F; Yoshisue, K	1
Boku, N; Doi, T; Fuse, N; Koizumi, W; Ohtsu, A; Shimada, K; Takinishi, Y; Yamazaki, K; Yoshino, T	1
Nakagawa, F; Nukatsuka, M; Takechi, T	1
Bendell, JC; Benedetti, F; Goldman, JW; Infante, JR; Lin, D; Mayer, RJ; Mizuguchi, H; Patel, MR; Rosen, LS; Zergebel, C	1
Lenz, HJ; Loupakis, F; Stintzing, S	1
Fujimoto, T; Katsube, T; Matsumoto, A; Nakayama, M; Naritaka, Y; Okayama, S; Sakuma, A; Satake, M; Shimakawa, T; Shiozawa, S; Usui, T; Yamaguchi, K; Yano, Y; Yokomizo, H; Yoshimatsu, K	1
Antoniotti, C; Cremolini, C; Falcone, A; Loupakis, F; Marmorino, F; Masi, G; Moretto, R; Rossini, D; Salvatore, L; Schirripa, M	1
Argiles, G; Elez, ME; Grasselli, J; Sanz-Garcia, E; Tabernero, J	1
Hochster, HS; Uboha, N	1
Baba, H; Lenz, HJ; Miyamoto, Y	1
Chen, J; Han, M; Saif, MW	1
Bando, H; Doi, T; Fukuoka, S; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Ohtsu, A; Okamoto, W; Shitara, K; Yoshino, T	1
Beumer, JH; Chu, E; Croft, M; Faulkner, T; Fawcett, P; Fiejdasz, J; Hague, J; Lee, JJ; Mason, S; Mizuguchi, H; Nugteren, J; Parise, RA; Pollice, L; Seraj, J; Strychor, S; Sun, W; Tedder, C; Yoshida, K	1
Baba, H; Iimori, M; Kitao, H; Maehara, Y; Matsuoka, K; Miyamoto, Y; Oki, E; Saeki, H; Tokunaga, E	1
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T	1
Goldberg, R	1
Akashi, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Kusaba, H; Makiyama, A; Matsushita, Y; Mitsugi, K; Shibata, Y; Shimokawa, HK; Shirakawa, T; Tamura, S	1
Opdam, FL; van der Velden, DL; Voest, EE	1
Arkenau, HT; Bendell, JC; Lemech, C; Pant, S; Patel, MR; Seraj, J; Todaro, TG; Weaver, R; Yoshida, K	1
Bando, H; Doi, T; Kuno, H; Muro, K; Nishina, T; Nomura, S; Ohtsu, A; Sato, A; Shitara, K; Takahashi, S; Yamaguchi, K; Yasui, H	1
Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T	1
Braghiroli, MI; Fonseca, LG; Hoff, PM; Mota, JM	1
Fujita, N; Furuta, T; Hara, N; Katori, J; Muro, K; Uetake, H; Yoshino, T	1
Barni, S; Bertocchi, P; Petrelli, F; Zaniboni, A	2
Cecchini, M; Grothey, A; Hochster, HS; Kasi, PM; Kotani, D; Ohtsu, A; Ramanathan, RK; Shitara, K; Yoshino, T	1
Argiles, G; Carrato-Mena, A; Cervantes, A; Garcia-Carbonero, R; Gil-Calle, S; Gravalos, C; Limón, ML; Longo-Muñoz, F; Mizuguchi, H; Pericay, C; Tabernero, J	1
Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H	1
Ando, M; Fukutomi, A; Hamauchi, S; Ishihara, M; Kadowaki, S; Kito, Y; Komori, A; Machida, N; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Tajika, M; Tanaka, T; Taniguchi, H; Todaka, A; Tsushima, T; Ura, T; Yamazaki, K; Yasui, H; Yokota, T	2
Andrikou, K; Berardi, R; Bianconi, M; Bittoni, A; Cabras, F; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Pusceddu, V; Restivo, A; Scartozzi, M; Scintu, F; Zorcolo, L	1
Benedetti, F; Cortinovis, D; Galetta, D; Inoue, A; Kubota, K; Makris, L; Niho, S; Nishio, M; Satouchi, M; Scagliotti, G; Valmadre, G; Yoshihara, E	1
Akagi, Y; Ishibashi, N; Kamei, H; Tanigawa, M; Uchida, M; Yamaguchi, K	1
Antonuzzo, L; Aprile, G; Baretti, M; Battaglin, F; Berenato, R; Beretta, G; Bozzarelli, S; Cinieri, S; Cremolini, C; de Braud, F; Falcone, A; Formica, V; Ghidini, M; Lonardi, S; Loupakis, F; Marmorino, F; Mennitto, A; Miceli, R; Morano, F; Mosconi, S; Petrelli, F; Pietrantonio, F; Rimassa, L; Rossini, D; Spada, D; Tamburini, E	1
Becerra, CR; Mizuguchi, H; Patel, M; Von Hoff, D; Yoshida, K	1
Hasegawa, J; Hirota, M; Kameda, C; Kawabata, R; Koga, C; Matsumura, T; Matsunami, N; Morishima, H; Murakami, M; Noura, S; Oda, N; Shimizu, J; Takata, A; Yasuyama, A	1
Chu, E; Lee, JJ	1
Alonso-Orduña, V; Capdevila, J; Hernando-Cubero, J; Matos-García, I	1
Barzi, A; Berger, MD; Cao, S; Gopez, R; Lenz, HJ; Loupakis, F; Marmorino, F; Mennitto, A; Miyamoto, Y; Murgioni, S; Ning, Y; Okazaki, S; Rossini, D; Schirripa, M; Suenaga, M; Yamaguchi, T; Yang, D; Zhang, W	1
Baba, Y; Ebara, S; Gotou, M; Nakamura, K; Satoh, Y; Sawada, H; Shibuya, K; Soeda, J; Tamura, T	1
Doi, T; Kajiwara, T; Kuboki, Y; Matsumoto, T; Mochizuki, N; Nishina, T; Nomura, S; Ohtsu, A; Okamoto, W; Sato, A; Shinozaki, E; Shitara, K; Tsushima, T; Yamazaki, K; Yoshino, T	1
Lonardi, S; Loupakis, F	1
Baba, E; Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Gosho, M; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, C; Moriwaki, T; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Sugiyama, M; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Watanabe, T; Yamashita, K; Yamazaki, K	1
Barzi, A; Berger, MD; Borelli, B; Cao, S; Dadduzio, V; Gopez, R; Lenz, HJ; Loupakis, F; Miyamoto, Y; Ning, Y; Okazaki, S; Pietrantonio, F; Salvatore, L; Schirripa, M; Suenaga, M; Yamaguchi, T; Yang, D; Zhang, W	1
Bullement, A; Fougeray, R; Hatswell, AJ; Underhill, S	1
Abrahao, ABK; Berry, S; Chan, KKW; Ko, YJ	1
Bebeau, P; Bendell, JC; Buscaglia, M; Falcone, A; Kopetz, S; Mayer, RJ; Ohtsu, A; Van Cutsem, E; Yoshino, T	1
Armstrong, N; Duffy, S; Fayter, D; Joore, MA; Kleijnen, J; Lang, S; Pouwels, X; Ramaekers, BLT; van Giessen, A; Wolff, R; Worthy, G	1
Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE	1
Iimori, M; Kiniwa, M; Kitao, H; Kurashige, J; Maehara, Y; Morodomi, Y; Nakanishi, R; Nakashima, Y; Oki, E; Saeki, H; Sugiyama, M	1
Ahn, JB; Bai, Y; Bi, F; Guo, W; Han, SW; Kim, TW; Li, J; Li, Q; Lin, D; Liu, T; Ma, D; Pan, H; Park, YS; Qin, S; Shen, L; Shi, C; Sriuranpong, V; Wu, C; Xu, J; Xu, R	1
Burki, TK	1
Benavides, M; Ciardiello, F; Denda, T; Grávalos, C; Laurent, S; Lenz, HJ; Loehrer, P; Longo-Munoz, F; Makris, L; Mayer, RJ; Muro, K; Ohtsu, A; Portales, F; Siena, S; Tsuji, Y; Van Cutsem, E; Winkler, R; Yamaguchi, K	1
Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T	1
Arnold, D; Moreno Vera, S; Mounedji, N; Prager, GW; Quintela, A; Stein, A; Taieb, J	1
Argilés, G; Élez, ME; Martini, G; Matos, I; Mulet, N; Noguerido, A; Tabernero, J	1
Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T	1
Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D	1
Li, J	1
Horiguchi, M; Sun, R; Wei, LJ	1
Addeo, A; Di Nardo, P	1
Akiba, T; Ishida, K; Kawahara, H; Matsumoto, N; Mouri, T; Yanaga, K	1
Arakawa, S; Asano, Y; Horiguchi, A; Imaeda, Y; Isetani, M; Ishihara, S; Ito, M; Ito, R; Kamio, K; Kawabe, N; Kawai, T; Nagata, H; Shimizu, K; Tomishige, H; Yasuoka, H	1
Cervantes, A; Moreno Vera, S; Peeters, M; Taieb, J	1
Antoniotti, C; Borelli, B; Ciardiello, F; Cremolini, C; Dal Maso, A; Di Bartolomeo, M; Falcone, A; Frassineti, GL; Lonardi, S; Martinelli, E; Masi, G; Miceli, R; Mosconi, S; Murgioni, S; Nichetti, F; Noventa, S; Pietrantonio, F; Rossini, D; Sforza, V; Tamburini, E; Troiani, T; Zucchelli, G	1
Garcia-Carbonero, R; Martinez-Perez, J; Riesco-Martinez, MC	1
Barghout, V; Duh, MS; Fuchs, CS; Patel, AK; Tabesh, M; Wynant, W; Xiao, Y; Yenikomshian, MA	1
Chu, E	1
Aisu, N; Daibo, K; Hasegawa, S; Kajitani, R; Kiyomi, F; Komono, A; Matsumoto, Y; Munechika, T; Sakamoto, R; Yoshida, Y	1
Bianconi, D; Drimmel, M; Gleiss, A; Kieler, M; Prager, GW; Scheithauer, W; Siebenhüner, A; Unseld, M; Winder, T	1
Baba, E; Denda, T; Esaki, T; Fukuoka, S; Ishikawa, T; Ito, M; Kajiwara, T; Kashiwada, T; Katsumata, K; Kishimoto, J; Komatsu, Y; Kumekawa, Y; Makiyama, A; Moriwaki, T; Oki, E; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Tsuchihashi, K; Ueno, H; Yamashita, K; Yamazaki, K	1
Kinoshita, H; Miki, A; Nakamura, D; Sugiyama, T; Tsubono, M; Uchida, S	1
Baba, H; Denda, T; Esaki, T; Fujii, H; Goto, M; Hamamoto, Y; Komatsu, Y; Moriwaki, T; Muro, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shinozaki, E; Sugimoto, N; Takayama, T; Tanase, T; Tsuji, A; Tsuji, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T	1
Barzi, A; Cho, SK; Hay, JW	1
Hiramatsu, M; Imai, Y; Kobayashi, T; Kono, E; Sakane, J; Suzuki, Y; Tsunematsu, I	1
Cohen, SJ; Grothey, A; Hochster, HS; Makris, L; Mayer, RJ; Winkler, R	1
Alsina, M; Arkenau, HT; Beretta, GD; Cutsem, EV; Doi, T; Dvorkin, M; Faustino, C; Fujitani, K; Ghidini, M; Gorbunova, V; Hosokawa, A; Ilson, DH; Makris, L; Mansoor, W; Nishikawa, K; Prokharau, A; Shitara, K; Tabernero, J; Winkler, RE; Yalçın, Ş; Zhavrid, E	1
Akiyama, T; Baba, H; Baba, Y; Eto, K; Hiyoshi, Y; Iwagami, S; Kiyozumi, Y; Miyamoto, Y; Yohei, N; Yoshida, N	1
Bebeau, P; Becerra, C; Rosen, L; Rudek, MA; Saif, MW; Shepard, DR; Sun, W; Winkler, R; Yamashita, F	1
Kimura, M; Teramachi, H; Usami, E; Yoshimura, T	1
Milano, G	1
Li, Q; Liao, W; Zhang, M; Zhou, J; Zhou, K	1
Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F	1
Ahn, DH; Bekaii-Saab, T; Benkhadra, R; Firwana, B; Hubbard, JM; Mody, K; Murad, MH; Sonbol, MB; Walden, DJ; Wang, Z	1
Carbajales-Álvarez, M; Carmona-Bayonas, A; Carriles, C; García, T; Jimenez-Fonseca, P; Lozano-Blázquez, A; Pimentel, P; Sánchez-Cánovas, M	1
Bonetti, A; Giuliani, J	2
Chan, BM; Hochster, HS; Lenz, HJ	1
Kawano, Y; Matsuda, A; Matsumoto, S; Sakurazawa, N; Sekiguchi, K; Shinozuka, E; Suzuki, H; Yamada, T; Yoshida, H	1
Bolzacchini, E; Giordano, M; Luchena, G	1
Afzal, AR; Brezden-Masley, C; Cheung, WY; Dolley, A; Samawi, HH	1
Bekaii-Saab, T; Grothey, A; Marshall, JL	1
Chen, J; Lin, H; Peng, Y; Wang, J	1
Ahn, DH; Alberts, SR; Bekaii-Saab, TS; Borad, MJ; Chakrabarti, S; Durgin, LM; Fruth, B; Hartgers, ML; Liu, MC; Mahipal, A; McWilliams, RR; Ou, FS; Walkes, RL; Wessling, J; Zemla, TJ	1
Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Hatachi, Y; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, A; Masuishi, T; Moriwaki, T; Oki, E; Sakai, D; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Tamura, T; Tsuchihashi, K; Tsuji, A; Ueno, H; Yamashita, K; Yamazaki, K	1
Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q	1
Bando, H; Horasawa, S; Kaneko, A; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Nakamura, Y; Shitara, K; Taniguchi, H; Tsuji, A; Yoshino, T	1
Grothey, A; Kasi, PM	1
Argilés, G; Baba, H; Benedetti, F; Cleary, JM; Esaki, T; Falcone, A; Garcia-Carbonero, R; Hamada, C; Hochster, HS; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Peeters, M; Shimada, Y; Shinozaki, E; Sobrero, A; Sugimoto, N; Tanase, T; Tran, B; Tsuji, A; Tsuji, Y; Van Cutsem, E; Yamaguchi, K; Yamashita, F; Yamazaki, K; Yoshino, T; Zaniboni, A	1
Amellal, NC; André, T; Falcone, A; Fougeray, R; Gandossi, E; Kanehisa, A; Saunders, M	1
Eng, C	1
Krogh, M; Möller, S; Petersen, LN; Pfeiffer, P; Poulsen, LØ; Qvortrup, C; Thomsen, KG; Winther, SB; Yilmaz, M; Zitnjak, D	1
Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D	1
Borner, M; De Dosso, S; Meisel, A; Siebenhüner, A; Wagner, AD	1
Fujii, H; Hirose, C; Iihara, H; Ishihara, T; Kitahora, M; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K	1
Burge, M; Chantrill, L; Gibbs, P; Pavlakis, N; Price, T; Shapiro, J; Sjoquist, K	1
Colloca, GA; Venturino, A	1
Möller, S; Pfeiffer, P; Qvortrup, C; Winther, SB	1
Kadowaki, S; Kawakami, T; Kawamoto, Y; Komatsu, Y; Masuishi, T; Muranaka, T; Muro, K; Nakatsumi, H; Omae, K; Onozawa, Y; Tajika, M; Taniguchi, H; Yamazaki, K; Yasui, H; Yuki, S	1
Aprile, G; Cianchi, F; Fancelli, S; Gatta Michelet, MR; Lavacchi, D; Mini, E; Nobili, S; Roviello, F; Roviello, G	1
Hatachi, Y; Kato, T; Kotaka, M; Ogata, M; Ogata, T; Satake, H; Tsuji, A; Yasui, H	1
Fukuoka, T; Hirakawa, K; Iseki, Y; Kashiwagi, S; Maeda, K; Nagahara, H; Ohira, M; Okazaki, Y; Shibutani, M; Wang, EN	1
Colaone, F; Hawkins, NS; Pollock, RF; Ross, PJ; Shergill, S; Walter, T	1
Hamada, S; Ikeda, J; Komatsu, S; Konishi, T; Matsubara, D; Shibata, R; Shimomura, K; Shioaki, Y; Soga, K; Taniguchi, F	1
Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A	1
Court, OR; Shemilt, K	1
Doi, T; Igarashi, A; Shitara, K; Takushima, Y; Yoshihara, H	1
Alsina, M; Arkenau, HT; Azcue, P; Catenacci, DVT; Doi, T; Fornaro, L; Fougeray, R; Ilson, DH; Lorenzen, S; Moreno, SR; Shitara, K; Tabernero, J; Van Cutsem, E; Zaanan, A	1
Cervantes, A; Ciardiello, D; Ciardiello, F; De Falco, V; Famiglietti, V; Fenocchio, E; Lombardi, P; Martinelli, E; Martini, G; Milanesio, M; Napolitano, S; Rosellò, S; Troiani, T; Vitale, P; Zanaletti, N	1
Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM	1
Abdel-Raouf, S; Angelis, V; Barry, A; Baxter, M; Chauhan, M; Eccles, B; Graham, JS; Hill, M; Holden, C; Iveson, T; Karampera, C; Khan, S; Martinou, M; Mills-Baldock, T; Pouptsis, A; Ross, PJ; Satterthwaite, L; Shiu, KK; Stavraka, C; Synowiec, A; Thomas, A; Young, S	1
Kaddah, MMY; Keshk, RM; Talaat, W	1
Giuliani, J	1
Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ	1
Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D	1
Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A	1
Amellal, N; Aubel, P; Cattan, V; Fougeray, R; Kim, TW; Li, J; Mayer, RJ; Ohtsu, A; Shen, L; Sriuranpong, V; Van Cutsem, E; Xuereb, L; Yoshino, T	1
Chucla, TC; De Castro, BA; de la Cámara Gomez, J; Diaz, SS; Fernández, FB; Lopez, MR; Martínez-Lago, N; Ponte, RV; Rendo, CR; Rodriguez, MIG; Salvador, MM; Suarez, BG	1
Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T	1
Arkenau, HT; Benhadji, KA; Doi, T; Falcone, A; George, B; Hochster, H; Ilson, DH; Makris, L; Mayer, R; Ohtsu, A; Shitara, K; Tabernero, J; Van Cutsem, E; Yoshino, T	1
de Castro, NM; García-Beloso, N; Gayoso-Rey, M; López-López, A; Piñeiro-Corrales, G; Robles-Torres, D; Romero-Ventosa, EY	1
Atreya, CE; Carnevale, J; Cinar, P; Fidelman, N; Griffith, M; Milloy, MA; Van Loon, K; Venook, AP	1
Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J	1
Antista, M; Antoniotti, C; Boccaccino, A; Borelli, B; Conca, V; Cremolini, C; Crucitta, S; Cucchiara, F; Danesi, R; Del Re, M; Germani, MM; Leone, AG; Marmorino, F; Masi, G; Moretto, R; Pietrantonio, F; Provenzano, L; Rossini, D; Spagnoletti, A	1
Cheung, WY; Ding, PQ; Dolley, A	1
Ikoma, T; Matsumoto, T; Miura, K; Nagai, H; Takatani, M; Tsuduki, T; Watanabe, T; Yamamura, S; Yasui, H	1
Florou, V; Garrido-Laguna, I; Haaland, B; Nevala-Plagemann, C; Sama, S; Shen, J; Ying, J	1
Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS	1
Fujii, H; Hirose, C; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Sadaka, S; Suzuki, A; Takahashi, T; Watanabe, D	1
Benhadji, KA; Doi, T; Ghidini, M; Hochster, H; Makris, L; Mansoor, W; Takahashi, O; Van Cutsem, E	1
Amellal, N; Benhadji, KA; Bondarenko, I; Ciardiello, F; Cremolini, C; Cruz, FM; Elez, E; Fakih, M; Leger, C; Liposits, G; Modest, DP; Pápai, Z; Poureau, PG; Prager, GW; Stroyakovskiy, D; Tabernero, J; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L	1
Furusawa, K; Furuse, J; Furuta, M; Hamaguchi, T; Hashimoto, I; Hayashi, K; Inokuchi, Y; Kanematsu, K; Machida, N; Maeda, S; Nagasawa, S; Notsu, A; Ogata, T; Onuma, S; Oshima, T; Suematsu, H; Watanabe, M; Yamada, T	1
Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M	1
Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T	1
Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S	1
Voutsadakis, IA	1
Andreozzi, V; Barros, AG; Brito-da-Silva, J; Costa, AL; Costa, L; Cruz, J; Dâmaso, S; Félix, J; Mansinho, A; Marques, D; Mota, M; Pinheiro, S; Pratas, E; Quintela, A; Rodrigues, J; Teixeira, AR	1
Kagawa, Y; Kunitomi, Y; Nakashima, M; Okude, R; Shinozaki, E; Tone, T	1
Doi, T; Ikeda, J; Ishikawa, T; Itoh, Y; Kirishima, T; Kudou, M; Kuriu, Y; Miyagawa, K; Nakanishi, M; Okayama, T; Otsuji, E; Takagi, T; Yoshida, N	1
Kawazoe, A; Kotani, D; Kuboki, Y; Mishima, S; Nakamura, H; Nakamura, Y; Okunaka, M; Shitara, K	1
Esaki, T; Fukuoka, S; Kajiwara, T; Kumekawa, Y; Makiyama, A; Masuishi, T; Moriwaki, T; Shimada, Y; Shiroyama, M; Takashima, A; Yamazaki, K	1
Fujii, H; Hirose, C; Hishida, S; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Suzuki, A; Tajima, JY; Takahashi, T; Watanabe, D	1

Reviews

31 review(s) available for trifluridine and uracil

Article	Year
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer science, 2007, Volume: 98, Issue:6 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Biological Availability; Clinical Trials as Topic; Drug Combinations; Drug Delivery Systems; Drug Resistance, Neoplasm; Forecasting; Gastrointestinal Neoplasms; Humans; Pyrimidines; Pyrrolidines; Thymidine; Thymine; Trifluridine; Uracil	2007
[Efficacy of TAS-102]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:1 Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil	2015
TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer treatment reviews, 2015, Volume: 41, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations; Humans; Neoplasms; Pyrrolidines; Thymine; Trifluridine; Uracil	2015
TAS-102 for the treatment of metastatic colorectal cancer. Expert review of anticancer therapy, 2015, Volume: 15, Issue:11 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Metastasis; Prognosis; Pyrrolidines; Survival Rate; Thymine; Trifluridine; Uracil	2015
Current and advancing treatments for metastatic colorectal cancer. Expert opinion on biological therapy, 2016, Volume: 16, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Combinations; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pyrrolidines; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Therapies, Investigational; Thymine; Trifluridine; Uracil; Vascular Endothelial Growth Factor A	2016
TAS-102: a novel antimetabolite for the 21st century. Future oncology (London, England), 2016, Volume: 12, Issue:2 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Clinical Trials as Topic; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neoplasms; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil	2016
A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Expert review of clinical pharmacology, 2016, Volume: 9, Issue:3 Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Neoplasm Metastasis; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Thymine; Trifluridine; Uracil	2016
TAS-102 an Emerging Oral Fluoropyrimidine. Anticancer research, 2016, Volume: 36, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Folic Acid Antagonists; Humans; Immunotherapy; Molecular Targeted Therapy; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil	2016
[Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:1 Topics: Animals; Cell Cycle; Colorectal Neoplasms; DNA; Drug Combinations; Drug Design; Drug Resistance, Neoplasm; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil	2016
TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 06-15, Volume: 22, Issue:12 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Pyrrolidines; Thymidylate Synthase; Thymine; Trifluridine; Uracil	2016
Review on TAS-102 development and its use for metastatic colorectal cancer. Critical reviews in oncology/hematology, 2016, Volume: 104 Topics: Animals; Clinical Trials as Topic; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil	2016
TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review. Clinical colorectal cancer, 2016, Volume: 15, Issue:4 Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Uracil	2016
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102). Clinical colorectal cancer, 2017, Volume: 16, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Humans; Medication Adherence; Neoplasm Metastasis; Pyrrolidines; Thymine; Trifluridine; Uracil	2017
The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. Journal of gastrointestinal cancer, 2017, Volume: 48, Issue:2 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Gastrointestinal Neoplasms; Humans; Molecular Targeted Therapy; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Pyrrolidines; Thymidine Phosphorylase; Thymidylate Synthase; Thymine; Trifluridine; Uracil	2017
A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. Clinical colorectal cancer, 2018, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil	2018
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2018, Volume: 36, Issue:3 Topics: Antineoplastic Agents; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Pyrrolidines; Technology Assessment, Biomedical; Thymine; Trifluridine; Uracil	2018
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4 Topics: Colorectal Neoplasms; Disease Progression; Drug Combinations; Drugs, Investigational; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil	2018
Fluoropyrimidine-induced cardiotoxicity. Critical reviews in oncology/hematology, 2018, Volume: 124 Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Humans; Neoplasms; Pyrimidines; Pyrrolidines; Quinazolines; Thiophenes; Thymine; Trifluridine; Uracil; Uridine	2018
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. Future oncology (London, England), 2018, Volume: 14, Issue:16 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colonic Neoplasms; Docetaxel; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Immunotherapy; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrrolidines; Quality of Life; Taxoids; Thymine; Trifluridine; Uracil	2018
The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. Expert opinion on drug safety, 2018, Volume: 17, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrrolidines; Survival Rate; Thymine; Treatment Outcome; Trifluridine; Uracil	2018
A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. The oncologist, 2019, Volume: 24, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Thymine; Treatment Outcome; Trifluridine; Uracil	2019
The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, Feb-21, Volume: 76, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Progression-Free Survival; Pyrrolidines; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil	2019
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials. Medical science monitor : international medical journal of experimental and clinical research, 2019, Dec-02, Volume: 25 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Quinazolines; Rectal Neoplasms; Thymine; Trifluridine; Uracil	2019
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? International journal of colorectal disease, 2020, Volume: 35, Issue:2 Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Thymine; Time Factors; Trifluridine; Uracil	2020
Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland. Oncology research and treatment, 2020, Volume: 43, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Drug Combinations; Humans; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Survival Rate; Switzerland; Thymine; Treatment Outcome; Trifluridine; Uracil	2020
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination. Critical reviews in oncology/hematology, 2020, Volume: 152 Topics: Antineoplastic Combined Chemotherapy Protocols; Biochemical Phenomena; Drug Combinations; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil	2020
Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Humans; Microspheres; Neoplasm Metastasis; Network Meta-Analysis; Palliative Care; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Uracil; Yttrium Radioisotopes	2020
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis. ESMO open, 2022, Volume: 7, Issue:3 Topics: Codon; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Mutation; Proto-Oncogene Proteins p21(ras); Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Uracil	2022
Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. Journal of geriatric oncology, 2023, Volume: 14, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Rectal Neoplasms; Trifluridine; Uracil	2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide	2023
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. Current oncology (Toronto, Ont.), 2023, 05-24, Volume: 30, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Rectal Neoplasms; Trifluridine; Uracil	2023

Trials

35 trial(s) available for trifluridine and uracil

Article	Year
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer, 2006, Sep-15, Volume: 107, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asthenia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil	2006
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Investigational new drugs, 2008, Volume: 26, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrrolidines; Thymine; Trifluridine; Uracil	2008
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer investigation, 2008, Volume: 26, Issue:8 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrrolidines; Thymine; Trifluridine; Uracil	2008
Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. British journal of cancer, 2012, Jul-24, Volume: 107, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrrolidines; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil	2012
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. The Lancet. Oncology, 2012, Volume: 13, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrrolidines; ras Proteins; Thymine; Trifluridine; Uracil	2012
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. The New England journal of medicine, 2015, May-14, Volume: 372, Issue:20 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrrolidines; Survival Analysis; Thymine; Trifluridine; Uracil	2015
TAS-102 for metastatic refractory colorectal cancer. The Lancet. Oncology, 2015, Volume: 16, Issue:7 Topics: Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrrolidines; Risk Assessment; Survival Analysis; Thymine; Treatment Outcome; Trifluridine; Uracil	2015
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Investigational new drugs, 2015, Volume: 33, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Proto-Oncogene Proteins p21(ras); Pyrrolidines; Thymine; Trifluridine; Uracil	2015
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Fatigue; Febrile Neutropenia; Female; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrrolidines; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil	2015
Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:3 Topics: Aged; Antineoplastic Agents; Chromatography, Liquid; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasms; Pyrimidines; Pyrrolidines; Tandem Mass Spectrometry; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil	2016
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. Cancer science, 2016, Volume: 107, Issue:5 Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Humans; Japan; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrrolidines; Thymine; Trifluridine; Uracil	2016
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:6 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Drug Administration Schedule; Drug Combinations; Electrocardiography; Electrocardiography, Ambulatory; Female; Heart; Humans; Male; Middle Aged; Neoplasms; Pyrrolidines; Thymine; Trifluridine; Uracil	2016
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). European journal of cancer (Oxford, England : 1990), 2016, Volume: 62 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil	2016
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017, Volume: 19, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Palliative Care; Prognosis; Pyrrolidines; Spain; Survival Rate; Thymine; Trifluridine; Uracil	2017
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung cancer (Amsterdam, Netherlands), 2016, Volume: 100 Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Platinum; Pyrrolidines; Small Cell Lung Carcinoma; Thymine; Topotecan; Treatment Outcome; Trifluridine; Uracil	2016
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 03-01, Volume: 28, Issue:3 Topics: Aged; Colon; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Combinations; Female; Humans; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Nomograms; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil	2017
A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil. Journal of clinical pharmacology, 2017, Volume: 57, Issue:6 Topics: Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasms; Pyrrolidines; Solutions; Tablets; Thymine; Treatment Outcome; Trifluridine; Uracil	2017
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. The Lancet. Oncology, 2017, Volume: 18, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Female; Humans; Japan; Male; Middle Aged; Pyrrolidines; Thymine; Trifluridine; Uracil	2017
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 02-01, Volume: 36, Issue:4 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Pyrrolidines; Thymine; Time Factors; Trifluridine; Uracil; Young Adult	2018
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. European journal of cancer (Oxford, England : 1990), 2018, Volume: 90 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil	2018
Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. Clinical colorectal cancer, 2018, Volume: 17, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Liver Neoplasms; Markov Chains; Palliative Care; Phenylurea Compounds; Prognosis; Pyridines; Pyrrolidines; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Thymine; Trifluridine; United States; Uracil	2018
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:6 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Pyrrolidines; Research Design; Thymine; Trifluridine; Uracil; Withholding Treatment	2018
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 2018, Volume: 19, Issue:11 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Combinations; Europe; Female; Humans; Israel; Japan; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Pyrrolidines; Stomach Neoplasms; Thymine; Time Factors; Trifluridine; United States; Uracil	2018
Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. British journal of clinical pharmacology, 2019, Volume: 85, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bilirubin; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Female; Humans; Liver; Liver Diseases; Male; Middle Aged; Models, Biological; Neoplasms; Pyrrolidines; Severity of Illness Index; Thymine; Treatment Outcome; Trifluridine; United States; Uracil	2019
Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. The oncologist, 2020, Volume: 25, Issue:5 Topics: Biliary Tract; Carcinoma; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil	2020
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. BMC cancer, 2019, Dec-27, Volume: 19, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil; Young Adult	2019
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:1 Topics: Colorectal Neoplasms; Drug Combinations; Humans; Japan; Neutropenia; Pyrrolidines; Thymine; Trifluridine; Uracil	2020
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. Future oncology (London, England), 2020, Volume: 16, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Pyrrolidines; Research Design; Thymine; Trifluridine; Uracil	2020
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. The Lancet. Oncology, 2020, Volume: 21, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrrolidines; Salvage Therapy; Survival Rate; Thymine; Trifluridine; Uracil	2020
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer. ESMO open, 2022, Volume: 7, Issue:6 Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Neutropenia; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil	2022
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with BMC cancer, 2022, Dec-13, Volume: 22, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Trifluridine; Uracil	2022
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023, Volume: 26, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Prognosis; Retrospective Studies; Stomach Neoplasms; Trifluridine; Uracil; Weight Loss	2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. The New England journal of medicine, 2023, May-04, Volume: 388, Issue:18 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Trifluridine; Uracil	2023
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study. The oncologist, 2023, Nov-02, Volume: 28, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Rectal Neoplasms; Trifluridine; Uracil	2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide	2023

Other Studies

119 other study(ies) available for trifluridine and uracil

Article	Year
Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. Biochemical pharmacology, 2000, May-15, Volume: 59, Issue:10 Topics: Administration, Oral; Animals; Antineoplastic Agents; Dogs; Drug Synergism; Enzyme Inhibitors; Female; Humans; Idoxuridine; Macaca fascicularis; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Placenta; Pyrrolidines; Recombinant Proteins; Structure-Activity Relationship; Thymidine; Thymidine Phosphorylase; Trifluridine; Uracil	2000
SYNTHESES OF 5-TRIFLUOROMETHYLURACIL AND 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE. Journal of medicinal chemistry, 1964, Volume: 7 Topics: Adenocarcinoma; Antineoplastic Agents; Chemistry, Pharmaceutical; Coliphages; DNA; DNA, Viral; Mice; Neoplasms, Experimental; Nucleosides; Pharmacology; Pyrimidines; Research; Trifluridine; Uracil	1964
FLUORINATED PYRIMIDINES. XXIV. IN VIVO METABOLISM OF 5-TRIFLUOROMETHYLURACIL-2-C-14 AND 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE-2-C-14. Cancer research, 1965, Volume: 25 Topics: Animals; Carbon Isotopes; Deoxyuridine; DNA; Fluorine; Metabolism; Mice; Neoplasms; Neoplasms, Experimental; Nucleosides; Pyrimidines; Radiometry; Research; Trifluridine; Uracil	1965
Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncology reports, 2004, Volume: 11, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Division; Drug Combinations; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Pyrrolidines; Stomach Neoplasms; Thymidine Kinase; Thymidine Phosphorylase; Thymidylate Synthase; Thymine; Transplantation, Heterologous; Trifluridine; Uracil	2004
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. International journal of molecular medicine, 2004, Volume: 13, Issue:4 Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Coloring Agents; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Globins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Chemical; Neoplasm Metastasis; Neoplasm Transplantation; Polymerase Chain Reaction; Pyrrolidines; Sensitivity and Specificity; Tetrazolium Salts; Thiazoles; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil	2004
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. International journal of oncology, 2004, Volume: 25, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Drug Combinations; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pyrrolidines; Rats; Rats, Nude; Stomach Neoplasms; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays	2004
Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor. Drug metabolism and pharmacokinetics, 2004, Volume: 19, Issue:3 Topics: Administration, Oral; Animals; Biological Availability; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Macaca fascicularis; Male; Models, Biological; Pyrrolidines; Rats; Rats, Sprague-Dawley; Species Specificity; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil	2004
American Society of Clinical Oncology--42nd annual meeting. Poster presentations on leukemia and cytotoxic chemotherapy. 2-6 June 2006, Atlanta, GA, USA. IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:8 Topics: Clinical Trials as Topic; Cytarabine; Drug Combinations; Gossypol; Humans; Leukemia; Mastocytosis, Systemic; Molecular Structure; Pyrimidines; Pyrrolidines; Thionucleotides; Thymine; Trifluridine; Uracil	2006
The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1 Topics: Administration, Oral; Animals; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Floxuridine; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Pyrrolidines; Sensitivity and Specificity; Thymidine Phosphorylase; Thymine; Treatment Outcome; Trifluridine; Tumor Cells, Cultured; Uracil; Xenograft Model Antitumor Assays	2007
Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. Oncology reports, 2010, Volume: 23, Issue:5 Topics: Antimetabolites, Antineoplastic; Drug Combinations; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Neoplasms; Patient Selection; Pyrimidines; Pyrrolidines; Thymidine Kinase; Thymidylate Synthase; Thymine; Trifluridine; Uracil	2010
TAS-102 in refractory colorectal cancer: caution is needed. The Lancet. Oncology, 2012, Volume: 13, Issue:10 Topics: Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Pyrrolidines; Thymine; Trifluridine; Uracil	2012
TAS-102: more than an antimetabolite. The Lancet. Oncology, 2012, Volume: 13, Issue:12 Topics: Colorectal Neoplasms; Female; Humans; Male; Trifluridine; Uracil	2012
Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines. Nucleosides, nucleotides & nucleic acids, 2014, Volume: 33, Issue:4-6 Topics: Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Combinations; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Pyrrolidines; Radiation-Sensitizing Agents; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil; Urinary Bladder Neoplasms	2014
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncology reports, 2014, Volume: 32, Issue:6 Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA, Neoplasm; Drug Combinations; Male; Mice, Inbred BALB C; Mice, Nude; Pyrrolidines; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays	2014
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer research, 2015, Volume: 35, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Mice; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays	2015
Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Dideoxynucleosides; Drug Combinations; Female; Fluorine Radioisotopes; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Pyrrolidines; Radiopharmaceuticals; Random Allocation; Thymidine Kinase; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays	2015
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncology reports, 2015, Volume: 33, Issue:5 Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cetuximab; Chromatography, Liquid; Colorectal Neoplasms; Disease Models, Animal; Drug Combinations; Humans; Male; Mice; Mice, Nude; Panitumumab; Pyrrolidines; Tandem Mass Spectrometry; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays	2015
Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells. Journal of pharmaceutical sciences, 2015, Volume: 104, Issue:9 Topics: Animals; Caco-2 Cells; Carrier Proteins; Cell Line, Tumor; Cell Membrane Permeability; Colorectal Neoplasms; Drug Combinations; Epithelial Cells; Humans; Intestinal Absorption; Intestine, Small; Membrane Transport Proteins; Nucleoside Transport Proteins; Nucleosides; Oocytes; Pyrrolidines; Thymine; Trifluridine; Uracil; Xenopus	2015
Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA. International journal of oncology, 2015, Volume: 46, Issue:6 Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA, Neoplasm; Drug Combinations; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Fluorouracil; HCT116 Cells; Humans; Male; Pyrophosphatases; Pyrrolidines; Substrate Specificity; Thymidine Kinase; Thymine; Trifluridine; Uracil	2015
TAS-102 prolongs overall survival in refractory colorectal cancer, study shows. BMJ (Clinical research ed.), 2015, May-14, Volume: 350 Topics: Adenocarcinoma; Colorectal Neoplasms; Female; Humans; Male; Trifluridine; Uracil	2015
Drug Improves Survival in Refractory Colorectal Cancer. Cancer discovery, 2015, Volume: 5, Issue:7 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Humans; Pyrrolidines; Survival Analysis; Thymine; Treatment Outcome; Trifluridine; Uracil	2015
Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2 Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA, Neoplasm; Drug Combinations; Humans; Leukocytes; Mice, Nude; Pyrrolidines; Thymine; Trifluridine; Tumor Stem Cell Assay; Uracil	2015
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts. Anticancer research, 2015, Volume: 35, Issue:9 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Death; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; HCT116 Cells; Humans; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Pyrrolidines; Stomach Neoplasms; Thymine; Treatment Outcome; Trifluridine; Tumor Burden; Uracil; Xenograft Model Antitumor Assays	2015
[Short-Term Outcome of TAS-102 for Refractory Metastatic Colorectal Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pyrrolidines; Retrospective Studies; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil	2015
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. Clinical colorectal cancer, 2016, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil	2016
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer. Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Retreatment; Thymine; Treatment Outcome; Trifluridine; Uracil	2016
Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer. Anticancer research, 2016, Volume: 36, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Salvage Therapy; Survival Analysis; Thymine; Treatment Outcome; Trifluridine; Uracil	2016
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. Die Pharmazie, 2016, Volume: 71, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Patient Safety; Pyrrolidines; Retrospective Studies; Tablets; Thymine; Trifluridine; Uracil; Vomiting	2016
In brief: trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer. The Medical letter on drugs and therapeutics, 2016, Jun-06, Volume: 58, Issue:1496 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Enzyme Inhibitors; Humans; Neoplasm Metastasis; Pyrrolidines; Thymidine Phosphorylase; Thymine; Treatment Outcome; Trifluridine; Uracil	2016
TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study. Clinical colorectal cancer, 2016, Volume: 15, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrrolidines; Thymine; Trifluridine; Uracil	2016
TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape? BMC cancer, 2016, 07-04, Volume: 16 Topics: Cardiotoxicity; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil	2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC cancer, 2016, 07-13, Volume: 16 Topics: Age Factors; Aged; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Clinical Trials, Phase III as Topic; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Pyrrolidines; Thymine; Trifluridine; United States; Uracil	2016
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. Anticancer research, 2016, Volume: 36, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Treatment Outcome; Trifluridine; Uracil	2016
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102. Clinical colorectal cancer, 2017, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neutropenia; Prognosis; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil	2017
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. Clinical colorectal cancer, 2017, Volume: 16, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Capecitabine; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil	2017
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. Clinical colorectal cancer, 2017, Volume: 16, Issue:2 Topics: Aged; Antineoplastic Agents; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Survival Rate; Thymine; Treatment Outcome; Trifluridine; Uracil	2017
Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report. Journal of medical case reports, 2016, Nov-03, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Japan; Lung Diseases, Interstitial; Male; Middle Aged; Pyrrolidines; Thymine; Trifluridine; Uracil	2016
[A Case of Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Treated with TAS-102 with Bevacizumab]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Pyrrolidines; Sigmoid Neoplasms; Thymine; Treatment Outcome; Trifluridine; Uracil	2016
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 05-01, Volume: 28, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; DNA Repair Enzymes; Drug Combinations; Drug Resistance, Neoplasm; Female; Genetic Association Studies; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Treatment Outcome; Trifluridine; Uracil	2017
Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine. Molecular oncology, 2017, Volume: 11, Issue:8 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drug Combinations; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Panitumumab; Pyrrolidines; Thymine; Trifluridine; Uracil	2017
New perspectives for TAS-102: TASK successful? The Lancet. Oncology, 2017, Volume: 18, Issue:9 Topics: Drug Combinations; Pyrrolidines; Thymine; Trifluridine; Uracil	2017
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. The oncologist, 2018, Volume: 23, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Propensity Score; Pyridines; Pyrrolidines; Retrospective Studies; Salvage Therapy; Survival Rate; Thymine; Trifluridine; Uracil	2018
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. European journal of cancer (Oxford, England : 1990), 2017, Volume: 86 Topics: Antineoplastic Agents; California; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gene Frequency; Genotype; Humans; Italy; Japan; Male; Neoplasm Metastasis; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyrrolidines; Retrospective Studies; Thymine; Treatment Outcome; Trifluridine; Uracil	2017
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales. Clinical colorectal cancer, 2018, Volume: 17, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; England; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Thymine; Trifluridine; Uracil; Wales	2018
Integrated safety summary for trifluridine/tipiracil (TAS-102). Anti-cancer drugs, 2018, Volume: 29, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Uracil	2018
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. International journal of clinical oncology, 2018, Volume: 23, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Netherlands; Neutropenia; Prognosis; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil	2018
Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication. Scientific reports, 2017, 12-05, Volume: 7, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone Marrow Cells; Colorectal Neoplasms; DNA; Drug Combinations; HCT116 Cells; Humans; Leukocytes, Mononuclear; Male; Mice, Inbred BALB C; Phytohemagglutinins; Pyrrolidines; Spleen; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays	2017
TAS-102 in metastatic colorectal cancer. The Lancet. Oncology, 2018, Volume: 19, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Treatment Outcome; Trifluridine; Uracil	2018
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer Die Pharmazie, 2017, Jan-10, Volume: 72, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prognosis; Pyrrolidines; Risk Factors; Survival Analysis; Thymine; Trifluridine; Uracil	2017
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:6 Topics: Colorectal Neoplasms; Drug Combinations; Humans; Prognosis; Pyrrolidines; Thymine; Trifluridine; Uracil	2018
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. Die Pharmazie, 2018, 03-05, Volume: 73, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Neutrophils; Pyrrolidines; Retrospective Studies; Risk Factors; Thymine; Trifluridine; Uracil	2018
Reply to P. Di Nardo et al and R. Sun et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 05-01, Volume: 36, Issue:13 Topics: Colonic Neoplasms; Double-Blind Method; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil	2018
Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 05-01, Volume: 36, Issue:13 Topics: Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Humans; Progression-Free Survival; Pyrrolidines; Respect; Thymine; Trifluridine; Uracil	2018
Statistical and Clinical Significance in the TERRA Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 05-01, Volume: 36, Issue:13 Topics: Double-Blind Method; Drug Combinations; Humans; Pyrrolidines; RNA, Long Noncoding; Telomere; Thymine; Trifluridine; Uracil	2018
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer. Anticancer research, 2018, Volume: 38, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pyrrolidines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thymine; Treatment Outcome; Trifluridine; Uracil	2018
[Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Humans; Liver Neoplasms; Male; Pyrrolidines; Rectal Neoplasms; Thymine; Treatment Outcome; Trifluridine; Uracil	2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. The oncologist, 2018, Volume: 23, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Progression-Free Survival; Pyrrolidines; Registries; Thymine; Trifluridine; Uracil	2018
Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib. Clinical colorectal cancer, 2018, Volume: 17, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Treatment Outcome; Trifluridine; United States; Uracil	2018
How I treat chemorefractory metastatic colorectal cancer. Clinical advances in hematology & oncology : H&O, 2018, Volume: 16, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Neoplasm Staging; Nivolumab; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thymine; Trastuzumab; Trifluridine; Uracil; Vascular Endothelial Growth Factor Receptor-1	2018
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. Anticancer research, 2018, Volume: 38, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neutropenia; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil	2018
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib. Clinical colorectal cancer, 2018, Volume: 17, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Phenylurea Compounds; Prognosis; Pyridines; Pyrrolidines; Retrospective Studies; Survival Rate; Thymine; Trifluridine; Uracil	2018
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Clinical colorectal cancer, 2018, Volume: 17, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Colorectal Neoplasms; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Nutritional Status; Phenylurea Compounds; Prognosis; Pyridines; Pyrrolidines; Retrospective Studies; Serum Albumin, Human; Survival Rate; Thymine; Trifluridine; Uracil	2018
[Two Cases of Long-Term Use of TAS-102 for Unresectable Colorectal Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:8 Topics: Aged, 80 and over; Appendiceal Neoplasms; Drug Combinations; Female; Humans; Male; Pyrrolidines; Rectal Neoplasms; Recurrence; Thymine; Treatment Outcome; Trifluridine; Uracil	2018
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. Clinical colorectal cancer, 2018, Volume: 17, Issue:4 Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Prognosis; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Rate; Thymidine Kinase; Thymine; Trifluridine; Uracil	2018
[A Case of Interstitial Pneumonitis Induced by TAS-102 for Liver and Lung Metastasis of Colorectal Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:9 Topics: Aged; Drug Combinations; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Pyrrolidines; Rectal Neoplasms; Sigmoid Neoplasms; Thymine; Treatment Outcome; Trifluridine; Uracil	2018
Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer. Digestion, 2019, Volume: 99, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscle, Skeletal; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyridines; Pyrrolidines; Retrospective Studies; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil	2019
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. Anticancer research, 2019, Volume: 39, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Pyrrolidines; Retrospective Studies; Tablets; Thymine; Treatment Outcome; Trifluridine; Uracil	2019
Fluoropyrimidines and DPD testing: is there truly an inexorable link? European journal of cancer (Oxford, England : 1990), 2019, Volume: 113 Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Fluorouracil; Genotype; Humans; Neoplasms; Oxonic Acid; Pharmacogenomic Testing; Phenotype; Point-of-Care Testing; Pyrrolidines; Tegafur; Thymine; Trifluridine; Uracil	2019
Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:3 Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Humans; Markov Chains; Progression-Free Survival; Pyrrolidines; Quality-Adjusted Life Years; Stomach Neoplasms; Thymine; Trifluridine; Uracil	2020
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Nomograms; Prognosis; Progression-Free Survival; Pyrrolidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Spain; Survival Rate; Thymine; Trifluridine; Uracil	2020
Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Severity of Illness Index; Thymine; Treatment Outcome; Trifluridine; Uracil	2019
The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. Anticancer research, 2019, Volume: 39, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neutropenia; Pyrrolidines; Survival Analysis; Thymine; Trifluridine; Uracil	2019
Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer. Anticancer research, 2019, Volume: 39, Issue:8 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Colorectal Neoplasms; Drug Combinations; Female; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Platelet Count; Prognosis; Progression-Free Survival; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil	2019
Safety Report of TAS-102 in a Patient With Reduced DPD Activity. Clinical colorectal cancer, 2019, Volume: 18, Issue:4 Topics: Aged; Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Patient Safety; Prognosis; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil	2019
Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada. Current oncology (Toronto, Ont.), 2019, Volume: 26, Issue:5 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Canada; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrrolidines; Thymine; Trifluridine; Uracil	2019
Sequencing beyond the second-line setting in metastatic colorectal cancer. Clinical advances in hematology & oncology : H&O, 2019, Volume: 17 Suppl 7, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Metastasis; Phenylurea Compounds; Prognosis; Pyridines; Pyrrolidines; Salvage Therapy; Survival Rate; Thymine; Trifluridine; Uracil	2019
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. International journal of clinical oncology, 2020, Volume: 25, Issue:4 Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Treatment Outcome; Trifluridine; Uracil	2020
Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:1 Topics: Colorectal Neoplasms; Drug Combinations; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine; Uracil	2020
TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer? The Lancet. Oncology, 2020, Volume: 21, Issue:3 Topics: Bevacizumab; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil	2020
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. BMC cancer, 2020, Feb-03, Volume: 20, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; United Kingdom; Uracil	2020
Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. The oncologist, 2020, Volume: 25, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil	2020
Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. Asia-Pacific journal of clinical oncology, 2020, Volume: 16 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Prognosis; Pyrrolidines; Quality of Life; Thymine; Trifluridine; Uracil	2020
TAS-102 plus bevacizumab in metastatic colorectal cancer. The Lancet. Oncology, 2020, Volume: 21, Issue:5 Topics: Bevacizumab; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil	2020
TAS-102 plus bevacizumab in metastatic colorectal cancer - Authors' reply. The Lancet. Oncology, 2020, Volume: 21, Issue:5 Topics: Bevacizumab; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil	2020
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. ESMO open, 2019, Volume: 4, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Time Factors; Trifluridine; Tumor Burden; Uracil	2019
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life. Clinical colorectal cancer, 2020, Volume: 19, Issue:4 Topics: Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; England; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil; Wales	2020
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. PloS one, 2020, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Retrospective Studies; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil	2020
Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer. Anticancer research, 2020, Volume: 40, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrrolidines; Survival Analysis; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil; Young Adult	2020
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Stomach Neoplasms; Survivors; Thymine; Trifluridine; Uracil	2020
[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab]. Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Thymine; Trifluridine; Uracil	2021
Lonsurf (trifluridine/tipiracil): Assessing the impact of dose related toxicities and progression free survival in (refractory) metastatic colorectal cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Progression-Free Survival; Rectal Neoplasms; Retrospective Studies; Trifluridine; Uracil	2022
Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan. Japanese journal of clinical oncology, 2021, Aug-30, Volume: 51, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Japan; Nivolumab; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil	2021
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO open, 2021, Volume: 6, Issue:4 Topics: Colorectal Neoplasms; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil	2021
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. Clinical colorectal cancer, 2021, Volume: 20, Issue:3 Topics: Colorectal Neoplasms; Drug Combinations; Humans; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil	2021
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. Current problems in cancer, 2022, Volume: 46, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Neoplasm Recurrence, Local; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Thymine; Trifluridine; Uracil	2022
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors. Clinical colorectal cancer, 2021, Volume: 20, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Prognosis; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil	2021
Selective sensing of the nucleoside analogue, trifluridine and tipiracil in dosage form and biological matrices. Talanta, 2022, Feb-01, Volume: 238, Issue:Pt 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Nucleosides; Pyrrolidines; Thymine; Trifluridine; Uracil	2022
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. Clinical colorectal cancer, 2022, Volume: 21, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil	2022
The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. Cancer treatment and research communications, 2022, Volume: 31 Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Liver Neoplasms; Male; Portugal; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Thymine; Trifluridine; Uracil	2022
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". Clinical colorectal cancer, 2022, Volume: 21, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil	2022
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. PloS one, 2022, Volume: 17, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil	2022
Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Scientific reports, 2022, 08-26, Volume: 12, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Thymine; Trifluridine; Uracil	2022
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. Targeted oncology, 2022, Volume: 17, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Retrospective Studies; Trifluridine; Uracil	2022
Regorafenib and trifluridine/tipiracil in real clinical practice. Journal of cancer research and therapeutics, 2022, Volume: 18, Issue:Supplement Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Male; Phenylurea Compounds; Retrospective Studies; Trifluridine; Uracil	2022
An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study. Clinical colorectal cancer, 2023, Volume: 22, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Immune Checkpoint Inhibitors; Rectal Neoplasms; Trifluridine; Uracil	2023
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients. Tumori, 2023, Volume: 109, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Rectal Neoplasms; Trifluridine; Uracil	2023
Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada. Current oncology (Toronto, Ont.), 2022, 12-22, Volume: 30, Issue:1 Topics: Adult; Aged; Canada; Colorectal Neoplasms; Esophageal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Stomach Neoplasms; Trifluridine; Uracil	2022
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab. Scientific reports, 2023, 02-10, Volume: 13, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil	2023
A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. Journal of the National Comprehensive Cancer Network : JNCCN, 2023, 02-22, Volume: 21, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Phenylurea Compounds; Prospective Studies; Rectal Neoplasms; Trifluridine; United States; Uracil	2023
Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy. Anticancer research, 2023, Volume: 43, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Nausea; Rectal Neoplasms; Risk Factors; Trifluridine; Uracil; Vomiting	2023
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer. Anticancer research, 2023, Volume: 43, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Irinotecan; Nivolumab; Stomach Neoplasms; Trifluridine; Uracil	2023
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. International journal of cancer, 2023, 09-15, Volume: 153, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Prospective Studies; Pyrrolidines; Quality of Life; Rectal Neoplasms; Trifluridine; Uracil	2023
Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil. Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Trifluridine; Uracil	2023
The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)), 2023, Volume: 35, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Rectal Neoplasms; Trifluridine; Uracil	2023
Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. ESMO open, 2023, Volume: 8, Issue:4 Topics: Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Japan; Retrospective Studies; Trifluridine; Uracil	2023
Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study. International journal of clinical oncology, 2023, Volume: 28, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Male; Middle Aged; Rectal Neoplasms; Retrospective Studies; Risk Factors; Trifluridine; Uracil	2023
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023, Volume: 26, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Trifluridine; Uracil	2023
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study. Scientific reports, 2023, 10-20, Volume: 13, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Neutropenia; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Risk Factors; Thymine; Trifluridine; Uracil	2023
Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias. BMC cancer, 2023, Nov-08, Volume: 23, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Neutropenia; Prognosis; Retrospective Studies; Trifluridine; Uracil	2023